I3A - Instituto de Investigación en Ingeniería de Aragón

Biomedical Engineering
Biomedical Engineering
Biomedical Engineering
Biomedical Engineering
Biomedical Engineering
Info
cerrarRadiotherapy treatment planning system
Biomedical Engineering
Biomedical Engineering
Info
cerrarBone modelling
Biomedical Engineering
Biomedical Engineering

The Biomedical Engineering Division is a clear example of the multidisciplinary approach of the I3A, as it brings together specialists in Biology, Medicine, Physics, Mathematics and Engineering who cooperate to develop technological applications to improve human health and quality of life. Current technologies for patient diagnosis, monitoring, therapy, surgery and solutions to help the disabled involve most fields of engineering. The specific research areas include:

  • Tissue engineering and biomaterials
  • Biological modeling and biomechanics
  • Imaging, signal and biomedical instruments
  • Healthcare and prevention technologies

 

Keywords

Mechanobiology, Biomaterials, tissue engineering, microfluidics, Bioreactors, diagnostic devices, cellular behavior modeling, microstructural behavior of biomaterials, heart electrophisiology, Telemedicine, Biomedical signals automatic coding methods, Biomedichal information transmission protocols, smart sensors, Computer visions algorithms for human detection, tracking and activity recognition, Prostheses design, Mesenchymal Stem Cells, Neurodegenerative diseases therapy, Prion Genetics and Genomics, Adapted human-machine interfaces, Indoor/outdoor location and guidance.


Key Projects

Many rare diseases cause chronic health problems or are even life-threatening. The impact on the quality of life of affected patients, of whom many are children, is significant. To date, a...
Many rare diseases cause chronic health problems or are even life-threatening. The impact on the quality of life of affected patients, of whom many are children, is significant. To date, a limited but increasing number of so-called orphan drugs (drugs for rare diseases) are reaching patients. However, the majority of rare diseases are still without any effective treatment. The development of novel human systems for drug discovery therefore represents a major public health priority.
 
Microfluidic technology-based “Organs-on-a-chip” represents a powerful tool for investigating rare disease mechanisms and testing new drug and treatment due to their ability to mimic tailored micro-environment architecture inspired by organ-level functions in vivo. However, due to the variability in rare disease mechanisms from one patient to another, organ on chip technology needs to be more precise and to convey towards personalized medicine.
 
The human-induced pluripotent stem cells (iPSCs) have a strong potential in engineering organ-on-a-chip since they are derived in a patient-matched manner which makes them a superb source to construct human models for personalized drug screening as well as for understanding patient-specific fundamentals of diseases.
 
To provide novel miniaturized platform for investigation of rare diseases able to address the burning issues in precision medicine today, CISTEM will bring together and synergistically several highly promising research directions which are too often investigated separately at the academic level but also at the industrial level. Based on 4 work packages, the CISTEM RISE project will be implemented by exploiting the complementary expertise of its partners and creating synergies between them through the targeted secondments of staff.
The CURABONE project aims to advance in the advancement and combination of different technologies, to achieve specific patient treatments in case of bone fractures.  In particular, it will focus...
The CURABONE project aims to advance in the advancement and combination of different technologies, to achieve specific patient treatments in case of bone fractures.  In particular, it will focus on cases of shoulder prostheses, knee prostheses, maxillofacial surgery and even tissue engineering. The ultimate goal is to help doctors make the best decisions for each patient and even planning their rehabilitation therapies. To achieve this goal, multiscale strategies will be developed that describe the problem from the biomechanics of the musculoskeletal system to the mechanobiological processes at the cellular level.
 
The CURABONE, ITN-EID project of Marie Curie actions financed by the European Commission (GA no 722535, H2020-MSCA-ITN-2016), is formed by a consortium of universities, companies and hospitals for the implementation of a European Industrial Doctorate (2017-2021). It is the first project of this type that is coordinated by the University of Zaragoza with a total budget of more than 1.2 million euros. 
Main reseacher: Esther Pueyo
 
MODELAGE proposes a multi-scale,multi-factorial research that is expected to make an important step in the characterization...
Main reseacher: Esther Pueyo
 
MODELAGE proposes a multi-scale,multi-factorial research that is expected to make an important step in the characterization of human heart aging at both the population and individual levels.
 
MODELAGE will work on an integrative methodological framework in which in silico modeling will be combined with in vitro cell and tissue analysis and in vivo electrocardiographic evaluation to investigate how cardiac aging manifests at a range of scales, from cell to body surface, and how electrical, structural and autonomic alterations contribute to such manifestations in humans.
 
By investigating the mechanisms underlying inter-individual differences in cardiac dynamics, MODELAGE will set links to arrhythmia susceptibility and will propose novel non-invasive markers to identify high-risk senescent individuals for which preventive anti-arrhythmic treatment
should be considered.
 
More info in:
The objective of POSITION-II is to bring innovation in the development and production of smart catheters by the introduction of open technology platforms for miniaturization, AD conversion at...
The objective of POSITION-II is to bring innovation in the development and production of smart catheters by the introduction of open technology platforms for miniaturization, AD conversion at the tip, ultra-sound MEMS devices and encapsulation.
 
Open technology platforms will generate the production volume that will enable sustainable innovation. The availability of open technology platforms will result in new instruments that have a better performance, new sensing and imaging capabilities, while the scale of volume will result in lower manufacturing costs. The production of the “brains” of these smart catheters will take place in Europe, with many European partners contributing essential technologies.
 
The POSITION-II project will consolidate Europe’s premier position as manufacturer of cath lab infrastructure since these new smart catheters will be seamlessly integrated in the cath lab hardware and software platforms. By combining the different sensing and imaging data a more intuitive cath lab experience will be achieved.
 
Looking forward, POSITION-II prepares the European electronics industry for the next revolution in healthcare, bioelectronics implants. Bioelectronics implants are expected to replace a considerable fraction of traditional medicine by direct stimulation of nerves. The miniaturization and soft encapsulation platforms developed in POSITION-II will be the ideal technology frame work for the manufacturing of these bioelectronics implants. The technology platforms developed in POSITION-II are demonstrated by five challenging product demonstrators covering FRR, IVUS, ICE, EP and cell therapy as well as a bioelectronics implant to treat cluster headache.
 
PRIMAGE will address the study of two types of pediatric cancer that have high mortality and therapeutic complexity: neuroblastoma and diffuse trunk-brain glioma.  The consortium will exploit...
PRIMAGE will address the study of two types of pediatric cancer that have high mortality and therapeutic complexity: neuroblastoma and diffuse trunk-brain glioma.  The consortium will exploit the precision information provided by the medical imaging to establish the characteristics of the tumors, their prognosis and the expected response to the treatment through what is known as radiometry, image biomarkers and artificial intelligence. This knowledge will be transferable to all European hospitals and centers specialized in this type of childhood cancer. Due to the peculiarities of the computational approach to these two types of childhood tumors, research in this field will also be applicable in other types of tumors.
 
In this project 16 European institutions of high prestige participate, it is financed with more than 10 million euros through the European Horizon2020 program, it will last 4 years and is one of the biggest milestones in funding and scientific recognition achieved in Spain.
 
Microfluidic devices manipulate tiny amounts of fluid enabling cost-effective, fast, accurate and high throughput analytical assays. Progress in Microfluidics has huge impact in environmental...
Microfluidic devices manipulate tiny amounts of fluid enabling cost-effective, fast, accurate and high throughput analytical assays. Progress in Microfluidics has huge impact in environmental pollution monitoring, biohazard detection and biomedicine, contributing to the development of new tools for drug screening, biological studies, point-of-care diagnostics and personalized medicine. Despite this huge potential, Microfluidics market growth is heavily constrained by the complexity and high prices of the required large-scale off-chip equipment and its operational cost. 
 
PRIME will use recently introduced 4D printing of liquid crystal elastomers for the direct implementation and integration of light-actuated valves and pumps in a microfluidic chip. Inkjet printing will produce new ultra sensitive and selective sensors embedded in the chip and readable with light. The final device will be remotely addressed and read using simple photonic elements that can be integrated in compact, portable and cheap operation&read devices. PRIME goes beyond the state-of-the-art generating a robust platform to create a new generation of active, tubeless and contactless microfluidic chips effectively changing the currently established paradigm.
 
PRIME will develop a radically new platform that:
  • integrates all the required responsive materials and elements in the chip, effectively providing it with all the fluidic and sensing functions
  • uses compatible materials and manufacturing technologies making future industrial production viable and cost-effective
  • allows to implement with extensive freedom of design a plethora of new smart-integrated and easy-to-operate microfluidic chips.
 
PRIME will thus narrow the gap between Microfluidics and non-specialized laboratories and end-users enabling the spread and penetration of the technology in diverse application fields as well as its geographical expansion to areas where large equipment is difficult to transport or resources are scarce.
© 2020 Instituto Universitario de Investigación en Ingeniería de Aragón - Universidad de Zaragoza | Policy